Caraco has addressed US 'Form 483' quality concerns, Sun confirms
This article was originally published in Scrip
Executive Summary
Sun Pharmaceutical Industries has said that its US arm, Caraco, has no pending unaddressed Form 483s, which pertain to the US FDA's observations on deficiencies in quality control systems, at its manufacturing sites, bringing relief to investors jittery over a spate of recent regulatory actions against a clutch of Indian firms.
You may also be interested in...
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet
Astellas CStO Pearson: We’re Not Short Of Opportunities To Compensate For LOEs
Astellas’ chief strategy officer, Adam Pearson, talks to Scrip about the company’s launch execution thrust for key therapies ahead of the loss of exclusivity for Xtandi and also deal-making appetite and choices, including the Iveric Bio buyout and walking away from the collaboration with Cartesian Therapeutics.